News & Updates

Show Multimedia Only

Ceperognastat no boon in early AD

30 Jul 2026

O-linked N-acetylglucosaminidase inhibition with ceperognastat falls short of slowing disease progression in patients with early Alzheimer’s disease (AD), according to a phase II study.

Ceperognastat no boon in early AD

30 Jul 2026

Healthy diets hold little long-term benefit for cognitive function in Asians

29 Jul 2026 by

Adherence to healthy dietary patterns offers no significant effect on the long-term risk of cognitive decline in a population-based cohort of older Singaporeans, researchers have found.

Healthy diets hold little long-term benefit for cognitive function in Asians

29 Jul 2026

GLP-1RA exposure lowers mortality in patients with dementia

25 Jul 2026 by

The use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to prevent all-cause deaths among patients with dementia, as shown in a retrospective cohort study presented at AAIC 2026.

GLP-1RA exposure lowers mortality in patients with dementia

25 Jul 2026

Blood test enables physicians to rule out Alzheimer’s disease in primary care

24 Jul 2026 by

A blood-based biomarker (BBM) test for Alzheimer’s disease (AD) allows primary care physicians to diagnose AD with the same precision as specialists, suggests a study presented at AAIC 2026.

Blood test enables physicians to rule out Alzheimer’s disease in primary care

24 Jul 2026

Venglustat superior to ERT in Gaucher disease type 3

24 Jul 2026 by

Treatment with oral venglustat demonstrates superior neurologic outcomes compared with standard enzyme replacement therapy (ERT) in patients with Gaucher disease type 3 (GD3), according to the phase III LEAP2MONO trial presented at EHA 2026.

Venglustat superior to ERT in Gaucher disease type 3

24 Jul 2026

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

23 Jul 2026

The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in an increased risk for ischaemic optic neuropathy (ION) at 18 months when compared with the use of sodium‒glucose cotransporter-2 inhibitors (SGLT2is) and dipeptidyl peptidase-4 inhibitors (DPP4is), reports a study.

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

23 Jul 2026

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

17 Jul 2026 by

Nearly a third of glioblastoma patients treated with standard radiotherapy plus temozolomide (STUPP protocol) suffer early-onset radiation induced leukoencephalopathy (RIL), which is linked to early cognitive and functional decline, according to a study.

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

17 Jul 2026

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

17 Jul 2026 by

The investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib demonstrates its noninferiority to ocrelizumab in reducing the risk of disability progression in patients with primary progressive multiple sclerosis (PPMS) in the phase III FENtrepid study.

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

17 Jul 2026

Does MS relapse after stopping ponesimod?

17 Jul 2026 by

In a post hoc analysis of the OPTIMUM* long-term extension (OPTIMUM-LTE) study, discontinuation of ponesimod did not lead to a clinically meaningful disease reactivation or rebound effect in patients with relapsing multiple sclerosis (MS).

Does MS relapse after stopping ponesimod?

17 Jul 2026

Older age, overweight raise risk of symptomatic VTE in DFF patients

16 Jul 2026 by

A Singapore study has observed a high prevalence of symptomatic venous thromboembolism (VTE) in patients who underwent distal femur fracture (DFF) surgery. Those with advanced age or who are overweight are more likely to develop symptomatic VTE.

Older age, overweight raise risk of symptomatic VTE in DFF patients

16 Jul 2026

News & Updates

Showing Neurology articles

Showing

Specialty:

Ceperognastat no boon in early AD

Ceperognastat no boon in early AD

Healthy diets hold little long-term benefit for cognitive function in Asians

Healthy diets hold little long-term benefit for cognitive function in Asians

GLP-1RA exposure lowers mortality in patients with dementia

GLP-1RA exposure lowers mortality in patients with dementia

Blood test enables physicians to rule out Alzheimer’s disease in primary care

Blood test enables physicians to rule out Alzheimer’s disease in primary care

Venglustat superior to ERT in Gaucher disease type 3

Venglustat superior to ERT in Gaucher disease type 3

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

Does MS relapse after stopping ponesimod?

Does MS relapse after stopping ponesimod?

Older age, overweight raise risk of symptomatic VTE in DFF patients

Older age, overweight raise risk of symptomatic VTE in DFF patients